Onsdag 30 Oktober | 09:26:59 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2025-02-13 08:00 Bokslutskommuniké 2024
2024-11-14 08:00 Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2024-05-22 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-07-12 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2023-06-01 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-03 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-12 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2022-05-05 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-03 - Bokslutskommuniké 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-07-09 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2021-05-06 - Årsstämma
2021-04-21 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-10-14 - Kvartalsrapport 2020-Q3
2020-07-10 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2020-05-07 - Årsstämma
2020-04-22 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-07-11 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning BIOA B 1.50 SEK
2019-05-09 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-16 - X-dag ordinarie utdelning BIOA B 0.00 SEK
2018-05-15 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriBioteknik
BioArctic är ett forskningsbolag. Störst affärsinriktning återfinns inom forskning och utveckling av behandlingar och antikroppar för sjukdomar som berör nervsystemet. Exempel på sjukdomar inkluderar främst Alzheimers och Parkinsons. En stor del av forskningen utförs i samarbete med forskare på universitet och sjukhus. Bolaget grundades under 2003 och har sitt huvudkontor i Stockholm.
2024-02-29 18:30:00

Stockholm, February 29, 2024 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued 7,700 Class B shares for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 7,700 options of series 2019/2028.

As of February 29, 2024, the last trading day of the month, the total number of shares in BioArctic AB amounts to 88,322,685 shares, of which 73,922,689 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 217,922,649. 

---

This information is information that BioArctic is obliged to make public pursuant to the Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact persons below, on February 29, 2024, at 18:30 CET.

For further information, please contact: 
Oskar Bosson, VP Communications and Investor Relations
E-mail:  oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80 

About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovation of treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.